Sacituzumab Govitecan in Recurrent Glioblastoma

Summary

This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.

Timeline

Start

2022-01-06

Primary completion

2027-02

Completion

2028-02

Drugs

Indications